Good glycaemic control can now be achieved with a lower risk of hypoglycaemia than before. Prof. Groop elaborates on the evidence on whether improving glycaemic control with DPP-4 inhibitors translates into a reduction of renal complications.
Recent outcome studies have shown evidence for a CV benefit with novel antidiabetic therapies such as DPP4 inhibitors and SGLT2 inhibitors. Dr. Pratley summarises the observations and speculates on how these findings may affect treatment of patients with diabetes in the near future.
Very recently, data became available of use of the SGLT2-inhibitor empagliflozin in patients with diabetic kidney disease, a condition associated with increased risk of CV complications. Prof. Groop shares the data that suggest that empagliflozin can reduce or prevent the onset of this condition.
Presentation prepared and held by Chaicharn Deerochanawong MD, Chulalongkorn University, Bangkok, Thailand at the Asian Interchange on Diabetes meeting held on July 30-31, 2016 in Bangkok, Thailand
Presentation prepared and held by Richard E. Pratley, MD, Florida Hospital Diabetes Institute, Orlando, Fl, USA at the Asian Interchange on Diabetes meeting held on July 30-31, 2016 in Bangkok, Thailand